A phase II, randomised study of mFOLFOX6 with or without the Akt inhibitor ipatasertib in patients with locally advanced or metastatic gastric or gastroesophageal junction cancer
Author:
Funder
F. Hoffmann-La Roche Ltd
Genentech, Inc.,
Astellas
AstraZeneca
Bayer
BeiGene
Boehringer Ingelheim
Boston Biomedical
Bristol-Meyers Squibb
CKD Pharma
Curis
Daiichi Sankyo
Eli Lilly
FivePrime
Genentech
Roche
GlaxoSmithKline
Green Cross
Hanmi
MacroGenics
Merck Serono
Merck Sharp & Dohme
Novartis
Ono
Otsuka
Pfizer
Taiho
Takeda
Ono and Taiho
Janssen-Cilag
Sanofi
Publisher
Elsevier BV
Subject
Cancer Research,Oncology
Reference21 articles.
1. Maximising the potential of AKT inhibitors as anti-cancer treatments;Brown;Pharmacol Ther,2017
2. Cisplatin induces PKB/Akt activation and p38(MAPK) phosphorylation of the EGF receptor;Winograd-Katz;Oncogene,2006
3. Landscape of phosphatidylinositol-3-kinase pathway alterations across 19784 diverse solid tumors;Millis;JAMA Oncol,2016
4. Comprehensive molecular characterization of gastric adenocarcinoma;Cancer Genome Atlas Research Network;Nature,2014
5. Clinicopathological significance of elevated PIK3CA expression in gastric cancer;Jang;J Gastric Cancer,2016
Cited by 32 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Molecular Targeting of the Phosphoinositide-3-Protein Kinase (PI3K) Pathway across Various Cancers;International Journal of Molecular Sciences;2024-02-06
2. Targeting PI3K/AKT/mTOR and MAPK Signaling Pathways in Gastric Cancer;International Journal of Molecular Sciences;2024-02-03
3. Cutaneous adverse reactions resulting from targeted cancer therapies: histopathologic and clinical findings;Human Pathology;2023-10
4. p70S6K/Akt dual inhibitor DIACC3010 is efficacious in preclinical models of gastric cancer alone and in combination with trastuzumab;Scientific Reports;2023-09-25
5. Ipatasertib exhibits anti‑tumorigenic effects and enhances sensitivity to paclitaxel in endometrial cancer in vitro and in vivo;International Journal of Oncology;2023-07-28
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3